Literature DB >> 17616646

Genetic and morphologic determinants of pneumothorax in lymphangioleiomyomatosis.

Wendy K Steagall1, Connie G Glasgow, Olanda M Hathaway, Nilo A Avila, Angelo M Taveira-Dasilva, Antoinette Rabel, Mario P Stylianou, Jing-Ping Lin, Xiaoling Chen, Joel Moss.   

Abstract

Lymphangioleiomyomatosis, a multisystem disease affecting women, is characterized by proliferation of abnormal smooth muscle-like cells in the lungs, leading to cystic destruction of the parenchyma and recurrent pneumothoraces. Clinical characteristics of lymphangioleiomyomatosis patients were analyzed to determine the relationship of pneumothoraces to disease progression. Patients were genotyped for polymorphisms in genes of extracellular matrix proteins collagen, elastin, and matrix metalloproteinase-1 to assess their association with pneumothoraces. Clinical data and polymorphisms in the genes for types I and III collagen, elastin, and matrix metalloproteinase-1 were compared with the prevalence of pneumothorax. Of 227 patients, 57% reported having had at least one pneumothorax. Cyst size on high-resolution computed tomography scans was associated with pneumothorax; patients with a history of pneumothorax were more likely to have larger cysts than patients who had no pneumothoraces. In patients with mild disease, those with a history of pneumothorax had a faster rate of decline in forced expiratory volume in 1 s (FEV(1); P = 0.001, adjusted for age) than those without. Genotype frequencies differed between patients with and without pneumothorax for polymorphisms in the types I and III collagen and matrix metalloproteinase-1 genes. Larger cysts may predispose lymphangioleiomyomatosis patients to pneumothorax, which, in early stages of disease, correlates with a more rapid rate of decline in FEV(1). Polymorphisms in types I and III collagen and matrix metalloproteinase-1 genes may cause differences in lung extracellular matrix that result in greater susceptibility to pneumothorax.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17616646     DOI: 10.1152/ajplung.00176.2007

Source DB:  PubMed          Journal:  Am J Physiol Lung Cell Mol Physiol        ISSN: 1040-0605            Impact factor:   5.464


  21 in total

1.  Incidence of Pneumothorax in Patients With Lymphangioleiomyomatosis Undergoing Pulmonary Function and Exercise Testing.

Authors:  Angelo M Taveira-DaSilva; Patricia Julien-Williams; Amanda M Jones; Joel Moss
Journal:  Chest       Date:  2016-07       Impact factor: 9.410

2.  Pneumothorax after air travel in lymphangioleiomyomatosis, idiopathic pulmonary fibrosis, and sarcoidosis.

Authors:  Angelo M Taveira-DaSilva; Dara Burstein; Olanda M Hathaway; Joseph R Fontana; Bernardette R Gochuico; Nilo A Avila; Joel Moss
Journal:  Chest       Date:  2009-03-24       Impact factor: 9.410

Review 3.  Spontaneous pneumothorax in diffuse cystic lung diseases.

Authors:  Joseph Cooley; Yun Chor Gary Lee; Nishant Gupta
Journal:  Curr Opin Pulm Med       Date:  2017-07       Impact factor: 3.155

Review 4.  The Genetics of Pneumothorax.

Authors:  Philip M Boone; Rachel M Scott; Stefan J Marciniak; Elizabeth P Henske; Benjamin A Raby
Journal:  Am J Respir Crit Care Med       Date:  2019-06-01       Impact factor: 21.405

5.  Lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Wendy K Steagall; Joel Moss
Journal:  Atlas Genet Cytogenet Oncol Haematol       Date:  2009

6.  Involvement of lymphatics in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Katsuya Tsukada; Xiong Cai; Souheil El-Chemaly; Joel Moss
Journal:  Lymphat Res Biol       Date:  2009-12       Impact factor: 2.589

7.  The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.

Authors:  Angelo M Taveira-DaSilva; Gustavo Pacheco-Rodriguez; Joel Moss
Journal:  Lymphat Res Biol       Date:  2010-03       Impact factor: 2.589

8.  Effects of prolactin on TSC2-null Eker rat cells and in pulmonary lymphangioleiomyomatosis.

Authors:  Yasuhiro Terasaki; Kinnosuke Yahiro; Gustavo Pacheco-Rodriguez; Wendy K Steagall; Mario P Stylianou; Jilly F Evans; Ameae M Walker; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2010-04-22       Impact factor: 21.405

9.  Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry.

Authors:  N Oprescu; F X McCormack; S Byrnes; B W Kinder
Journal:  Lung       Date:  2012-09-25       Impact factor: 2.584

Review 10.  Lymphatic involvement in lymphangioleiomyomatosis.

Authors:  Connie G Glasgow; Angelo M Taveira-Dasilva; Thomas N Darling; Joel Moss
Journal:  Ann N Y Acad Sci       Date:  2008       Impact factor: 5.691

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.